<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22563515</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>5</Issue><PubDate><Year>2012</Year></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Development of a humanized antibody with high therapeutic potential against dengue virus type 2.</ArticleTitle><Pagination><StartPage>e1636</StartPage><MedlinePgn>e1636</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1636</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0001636</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Dengue virus (DENV) is a significant public health threat in tropical and subtropical regions of the world. A therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">We generated seventeen novel mouse monoclonal antibodies (mAbs) with high reactivity against E protein of dengue virus type 2 (DENV-2). The mAbs were further dissected using recombinant E protein domain I-II (E-DI-II) and III (E-DIII) of DENV-2. Using plaque reduction neutralization test (PRNT) and mouse protection assay with lethal doses of DENV-2, we identified four serotype-specific mAbs that had high neutralizing activity against DENV-2 infection. Of the four, E-DIII targeting mAb DB32-6 was the strongest neutralizing mAb against diverse DENV-2 strains. Using phage display and virus-like particles (VLPs) we found that residue K310 in the E-DIII A-strand was key to mAb DB32-6 binding E-DIII. We successfully converted DB32-6 to a humanized version that retained potency for the neutralization of DENV-2 and did not enhance the viral infection. The DB32-6 showed therapeutic efficacy against mortality induced by different strains of DENV-2 in two mouse models even in post-exposure trials.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">We used novel epitope mapping strategies, by combining phage display with VLPs, to identify the important A-strand epitopes with strong neutralizing activity. This study introduced potential therapeutic antibodies that might be capable of providing broad protection against diverse DENV-2 infections without enhancing activity in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pi-Chun</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Mei-Ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Ping-Chang</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Jian-Jong</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>I-Ju</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Chiu</LastName><ForeName>Chien-Yu</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Yi-Ling</ForeName><Initials>YL</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chung</ForeName><Initials>HC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>05</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003715" MajorTopicYN="N">Dengue</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018604" MajorTopicYN="N">Epitope Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="N">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010948" MajorTopicYN="N">Viral Plaque Assay</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>5</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22563515</ArticleId><ArticleId IdType="pmc">PMC3341331</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0001636</ArticleId><ArticleId IdType="pii">PNTD-D-11-01097</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, et al. Dengue: a continuing global threat. Nat Rev Microbiol. 2010;8:S7&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333201</ArticleId><ArticleId IdType="pubmed">21079655</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Dengue. Lancet. 2007;370:1644&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">17993365</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis. 1997;176:313&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">9237695</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice CM, Lenches EM, Eddy SR, Shin SJ, Sheets RL, et al. Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science. 1985;229:726&#x2013;733.</Citation><ArticleIdList><ArticleId IdType="pubmed">4023707</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe. 2008;4:229&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2678546</ArticleId><ArticleId IdType="pubmed">18779049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokidysheva E, Zhang Y, Battisti AJ, Bator-Kelly CM, Chipman PR, et al. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell. 2006;124:485&#x2013;493.</Citation><ArticleIdList><ArticleId IdType="pubmed">16469696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108:717&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003;100:6986&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT. Antigenic structure of flavivirus proteins. Adv Virus Res. 2003;59:141&#x2013;175.</Citation><ArticleIdList><ArticleId IdType="pubmed">14696329</ArticleId></ArticleIdList></Reference><Reference><Citation>Mukhopadhyay S, Kuhn RJ, Rossmann MG. A structural perspective of the flavivirus life cycle. Nat Rev Microbiol. 2005;3:13&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">15608696</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Chang GJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78:13975&#x2013;13986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533943</ArticleId><ArticleId IdType="pubmed">15564505</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008;82:8828&#x2013;8837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519678</ArticleId><ArticleId IdType="pubmed">18562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998;246:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, et al. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol. 2009;90:799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2889437</ArticleId><ArticleId IdType="pubmed">19264660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15:312&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">18264114</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81:12816&#x2013;12826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev. 1998;11:480&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC88892</ArticleId><ArticleId IdType="pubmed">9665979</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4:e4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt AC. Response to dengue fever&#x2013;the good, the bad, and the ugly? N Engl J Med. 2010;363:484&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">20818870</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265:739&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">404559</ArticleId></ArticleIdList></Reference><Reference><Citation>Littaua R, Kurane I, Ennis FA. Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection. J Immunol. 1990;144:3183&#x2013;3186.</Citation><ArticleIdList><ArticleId IdType="pubmed">2139079</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang KJ, Yang YC, Lin YS, Huang JH, Liu HS, et al. The dual-specific binding of dengue virus and target cells for the antibody-dependent enhancement of dengue virus infection. J Immunol. 2006;176:2825&#x2013;2832.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Liao CL, Chen LK, Yeh CT, Liu CI, et al. Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol. 1998;72:9729&#x2013;9737.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC110483</ArticleId><ArticleId IdType="pubmed">9811707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, et al. CLEC5A is critical for dengue-virus-induced lethal disease. Nature. 2008;453:672&#x2013;676.</Citation><ArticleIdList><ArticleId IdType="pubmed">18496526</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HC, Jung MY, Chiu CY, Chao TT, Lai SC, et al. Identification of a dengue virus type 2 (DEN-2) serotype-specific B-cell epitope and detection of DEN-2-immunized animal serum samples using an epitope-based peptide antigen. J Gen Virol. 2003;84:2771&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pubmed">13679612</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Huang HN, Lin CT, Chen YF, King CC, et al. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007;14:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865613</ArticleId><ArticleId IdType="pubmed">17287314</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu CY, Hsu YW, Liao CL, Lin YL. Flavivirus infection activates the XBP1 pathway of the unfolded protein response to cope with endoplasmic reticulum stress. J Virol. 2006;80:11868&#x2013;11880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1642612</ArticleId><ArticleId IdType="pubmed">16987981</ArticleId></ArticleIdList></Reference><Reference><Citation>Durbin JE, Hackenmiller R, Simon MC, Levy DE. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996;84:443&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">8608598</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu IJ, Chiu CY, Chen YC, Wu HC. Molecular mimicry of human endothelial cell antigen by autoantibodies to nonstructural protein 1 of dengue virus. J Biol Chem. 2011;286:9726&#x2013;9736.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3058979</ArticleId><ArticleId IdType="pubmed">21233208</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang GJ, Hunt AR, Holmes DA, Springfield T, Chiueh TS, et al. Enhancing biosynthesis and secretion of premembrane and envelope proteins by the chimeric plasmid of dengue virus type 2 and Japanese encephalitis virus. Virology. 2003;306:170&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">12620809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631&#x2013;6643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubel S, Breitling F, Fuchs P, Zewe M, Gotter S, et al. Isolation of IgG antibody Fv-DNA from various mouse and rat hybridoma cell lines using the polymerase chain reaction with a simple set of primers. J Immunol Methods. 1994;175:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">7930642</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlandi R, Gussow DH, Jones PT, Winter G. Cloning immunoglobulin variable domains for expression by the polymerase chain reaction. Proc Natl Acad Sci U S A. 1989;86:3833&#x2013;3837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287235</ArticleId><ArticleId IdType="pubmed">2726754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37:D1006&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2686541</ArticleId><ArticleId IdType="pubmed">18978023</ArticleId></ArticleIdList></Reference><Reference><Citation>Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007;449:101&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">17805298</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8:271&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg. 1982;31:548&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">6177259</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabin AB, Schlesinger RW. Production of Immunity to Dengue with Virus Modified by Propagation in Mice. Science. 1945;101:640&#x2013;642.</Citation><ArticleIdList><ArticleId IdType="pubmed">17844088</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Purcell RH, Lai CJ. Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein. J Virol. 2004;78:12919&#x2013;12928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC525008</ArticleId><ArticleId IdType="pubmed">15542644</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010;6:e1000823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010;84:9227&#x2013;9239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu IJ, Hsueh PR, Lin CT, Chiu CY, Kao CL, et al. Disease-specific B Cell epitopes for serum antibodies from patients with severe acute respiratory syndrome (SARS) and serologic detection of SARS antibodies by epitope-based peptide antigens. J Infect Dis. 2004;190:797&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109815</ArticleId><ArticleId IdType="pubmed">15272409</ArticleId></ArticleIdList></Reference><Reference><Citation>LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A. 1989;86:4220&#x2013;4224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC287422</ArticleId><ArticleId IdType="pubmed">2726771</ArticleId></ArticleIdList></Reference><Reference><Citation>Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A. 1994;91:969&#x2013;973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC521435</ArticleId><ArticleId IdType="pubmed">8302875</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc Natl Acad Sci U S A. 2007;104:9422&#x2013;9427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1868655</ArticleId><ArticleId IdType="pubmed">17517625</ArticleId></ArticleIdList></Reference><Reference><Citation>Bublil EM, Freund NT, Mayrose I, Penn O, Roitburd-Berman A, et al. Stepwise prediction of conformational discontinuous B-cell epitopes using the Mapitope algorithm. Proteins. 2007;68:294&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">17427229</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med. 2005;11:522&#x2013;530.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1458527</ArticleId><ArticleId IdType="pubmed">15852016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu HC, Huang YL, Chao TT, Jan JT, Huang JL, et al. Identification of B-cell epitope of dengue virus type 1 and its application in diagnosis of patients. J Clin Microbiol. 2001;39:977&#x2013;982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC87860</ArticleId><ArticleId IdType="pubmed">11230414</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol. 2006;80:6982&#x2013;6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489037</ArticleId><ArticleId IdType="pubmed">16809304</ArticleId></ArticleIdList></Reference><Reference><Citation>de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5:e1188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3119640</ArticleId><ArticleId IdType="pubmed">21713020</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Chien CH, Tubthong K, Gorshkova I, Roll C, et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol. 2008;82:7009&#x2013;7021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446956</ArticleId><ArticleId IdType="pubmed">18480437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CJ, Goncalvez AP, Men R, Wernly C, Donau O, et al. Epitope determinants of a chimpanzee dengue virus type 4 (DENV-4)-neutralizing antibody and protection against DENV-4 challenge in mice and rhesus monkeys by passively transferred humanized antibody. J Virol. 2007;81:12766&#x2013;12774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169078</ArticleId><ArticleId IdType="pubmed">17881450</ArticleId></ArticleIdList></Reference><Reference><Citation>Sultana H, Foellmer HG, Neelakanta G, Oliphant T, Engle M, et al. Fusion loop peptide of the West Nile virus envelope protein is essential for pathogenesis and is recognized by a therapeutic cross-reactive human monoclonal antibody. J Immunol. 2009;183:650&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3690769</ArticleId><ArticleId IdType="pubmed">19535627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yauch LE, Shresta S. Mouse models of dengue virus infection and disease. Antiviral Res. 2008;80:87&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048811</ArticleId><ArticleId IdType="pubmed">18619493</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>